Old Web
English
Sign In
Acemap
>
authorDetail
>
Jun Zhang
Jun Zhang
Celgene
Fedratinib
Medicine
Myelofibrosis
Internal medicine
Ruxolitinib
3
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib
2019
Blood
Claire N. Harrison
Nicolaas Schaap
Alessandro M. Vannucchi
Jean-Jacques Kiladjian
Francesco Passamonti
Sonja Zweegman
Moshe Talpaz
Srdan Verstovsek
Shelonitda Rose
Jun Zhang
Tymara Berry
Carrie Brownstein
Ruben A. Mesa
Show All
Source
Cite
Save
Citations (9)
Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts
2019
Clinical Lymphoma, Myeloma & Leukemia
Claire N. Harrison
Nicolaas Schaap
Alessandro M. Vannucchi
Jean-Jacques Kiladjian
Francesco Passamonti
Sonja Zweegman
Moshe Talpaz
Srdan Verstovsek
Torsten Gerike
Shelonitda Rose
Jun Zhang
Tymara Berry
Carrie Brownstein
Ruben A. Mesa
Show All
Source
Cite
Save
Citations (4)
FREEDOM: A phase 3b efficacy and safety study of fedratinib in intermediate- or high-risk myelofibrosis patients previously treated with ruxolitinib.
2019
Journal of Clinical Oncology
Srdan Verstovsek
Claire N. Harrison
Giovanni Barosi
Jean-Jacques Kiladjian
Daniela Buglio
Vincent Chia
Torsten Gerike
Valerie Jessent-Ciaravino
Joseph Mostillo
Jun Zhang
Ruben A. Mesa
Show All
Source
Cite
Save
Citations (2)
1